MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cytokinetics Company Profile (NASDAQ:CYTK)

Consensus Ratings for Cytokinetics (NASDAQ:CYTK) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.29 (125.47% upside)

Analysts' Ratings History for Cytokinetics (NASDAQ:CYTK)
Show:
DateFirmActionRatingPrice TargetActions
5/25/2016Piper JaffrayReiterated RatingOverweight$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$16.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/17/2016Cowen and CompanyReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015MLV & Co.Reiterated RatingBuy$9.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/28/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha